Research
Hormonal
Anti-obesity medications (AOMs) are underutilized in China due to limited approved options and physician preference for lifestyle interventions, despite high patient willingness to try new AOMs.
If you are a physician in China, be aware that AOMs are underutilized due to limited options and safety concerns. However, patients are willing to try new AOMs. As new AOMs become available, consider prescribing them for patients who fail lifestyle interventions.
ModerateSupportsMEDIUM confidence
Physicians typically initiated lifestyle interventions as first-line treatment despite low PwO compliance... Of the 78 physicians who used anti-obesity medications (AOMs), the single most important reason for initiating AOM was failure to reach the desired weight loss with diet and exercise alone (58%).
Why this rating
Cross-sectional survey data.
Source
Current status, perceptions, and barriers regarding weight loss approaches in China
Ziwei Lin et al. · Endocrine · 2025
DOI 10.1007/s12020-025-04315-7
cross_sectional · n=901Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →